# US 2025/0154231 A1 · Antibodies capable of binding to the spike protein of cononavirus sars-cov-2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154231 A1
- Document ID: US20250154231A1
- Status: Published application
- Kind: A1
- Application number: 18/839,067
- Filed: 2023-02-17
- Published: 2025-05-15
- Earliest claimed: 2022-02-18
- Assignees: Rqbio Covid Limited
- Applicants: Rqbio Covid Limited
- Inventors: Juthathip MONGKOLSAPAYA; Gavin SCREATON
- Web page: https://patentgrep.com/patent/US20250154231A1

## CPC

- C07K 16/10: RNA viruses
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- G01N 33/56983: {Viruses}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.

## Claims

### Claim 1

An antibody capable of binding to the spike protein of coronavirus SARS-CoV-2, wherein the antibody comprises at least three CDRs of antibody Omi12, or of any one of the 27 antibodies in Table 3.

### Claim 2 (depends on 1)

The antibody according to claim 1, comprising:
(a) at least four, five, or all six CDRs of an antibody in Table 3;
(b) a heavy chain variable domain comprising or consisting of an amino acid sequence having at least 80% sequence identity to the heavy chain variable domain of an antibody in Table 3;
(c) a light chain variable domain comprising or consisting of an amino acid sequence having at least 80% sequence identity to the light chain variable domain of an antibody in Table 3; and/or
(d) a heavy chain variable domain and a light chain variable domain comprising or consisting of an amino acid sequence having at least 80% identity to the heavy chain variable domain and light chain domain, respectively, of an antibody in Table 3.

### Claim 3 (depends on 1, 2)

The antibody of claim 1 or claim 2, wherein the antibody in Table 3 is selected from the group consisting of:
(a) Omi02, Omi03, Omi12, Omi18, Omi28, Omi39 and Omi42;
(b) Omi03 and Omi12;
(c) Omi03, Omi12, Omi02, Omi39, and Omi42;
(d) Omi03, Omi12, Omi02, Omi39, Omi42, Omi16, Omi18, Omi20, Omi23, Omi28 and Omi08; or
(e) Omi03, Omi12, Omi02, Omi39, Omi42, Omi16, Omi18, Omi20, Omi 23, Omi28, Omi08, Omi17, Omi29, Omi36 and Omi38.

### Claim 4 (depends on 1)

The antibody according to claim 1, comprising CDRH1, CDRH2 and CDRH3, from a first antibody in any one of Tables 1 to 3, and CDRL1, CDRL2 and CDRL3 from a second antibody in any one of Tables 1 to 3, with the proviso that the first antibody and the second antibody are different.

### Claim 5 (depends on 4)

The antibody according to claim 4, comprising a heavy chain variable domain amino acid sequence having at least 80% sequence identity to the heavy chain variable domain from a first antibody in any one of Tables 1 to 3, and a light chain variable domain amino acid sequence having at least 80% sequence identity to the light chain variable domain from a second antibody in any one of Tables 1 to 3.

### Claim 6 (depends on 4, 5)

The antibody according to claim 4 or claim 5, wherein the first and second antibodies derive from the same germline heavy chain v-region, optionally wherein the heavy chain v-region is IGHV1-69, IGHV3-53, IGHV1-58, IGHV3-66, IGHV3-30, IGHV3-33, IGHV1-18, IGHV3-9, or IGHV4-31.

### Claim 7 (depends on 4, 5, 6)

The antibody according to any one of claims 4 to 6, wherein the first antibody and the second antibody are both selected from the group consisting of:
(a) Omi03, Omi18, Omi29, Beta-27, antibody 150, antibody 158, antibody 175, antibody 222 and antibody 269; optionally wherein the antibody comprises heavy chain variable domain and light chain variable domain of one of the antibodies as set out in Table 4;
(b) Omi03, Omi18, Omi29, Omi16, Omi17, Omi20, Omi27, Omi36, Beta-27, antibody 150, antibody 158, antibody 175, antibody 222, antibody 269, antibody 40 and antibody 398; optionally wherein the antibody comprises heavy chain variable domain and light chain variable domain of one of the antibodies as set out in Table 5;
(c) Omi12, Beta-47, Beta-25, antibody 55, antibody 165, antibody 253 and antibody 318; optionally wherein the antibody comprises heavy chain variable domain and light chain variable domain of one of the antibodies as set out in Table 6;
(d) Beta-49, Beta-50, Omi02, Omi24, Omi30, Omi31, Omi34 and Omi38; optionally wherein the antibody comprises heavy chain variable domain and light chain variable domain of one of the antibodies as set out in Table 7;
(e) Beta-22, Beta-29, antibody 159 and Omi09; optionally wherein the antibody comprises heavy chain variable domain and light chain variable domain of one of the antibodies as set out in Table 8;
(f) Beta-20, Beta-43, Omi32 and Omi33; optionally wherein the antibody comprises heavy chain variable domain and light chain variable domain of one of the antibodies as set out in Table 9;
(g) antibody 278, Beta-44, Omi26 and Omi41; optionally wherein the antibody comprises heavy chain variable domain and light chain variable domain of one of the antibodies as set out in Table 10;
(h) antibody 58, Omi25, Omi35 and Omi42; optionally wherein the antibody comprises heavy chain variable domain and light chain variable domain of one of the antibodies as set out in Table 11; or
(i) Beta-56 and Omi23; optionally wherein the antibody comprises heavy chain variable domain and light chain variable domain of one of the antibodies as set out in Table 12.

### Claim 8

The antibody of any one of the preceding claims, wherein the antibody in Tables 3 to 12 is selected from the group consisting of:
(a) Omi02, Omi03, Omi12, Omi18, Omi28, Omi39 and Omi42;
(b) Omi03 and Omi12;
(c) Omi03, Omi12, Omi02, Omi39, and Omi42;
(d) Omi03, Omi12, Omi02, Omi39, Omi42, Omi16, Omi18, Omi20, Omi23, Omi28 and Omi08; or
(e) Omi03, Omi12, Omi02, Omi39, Omi42, Omi16, Omi18, Omi20, Omi 23, Omi28, Omi08, Omi17, Omi29, Omi36 and Omi38.

### Claim 9

The antibody according to any one of the preceding claims, which is a full-length antibody, e.g. comprising a IgG1 constant region, or comprises an Fc region comprising at least one modification such that serum half-life is extended.

### Claim 10

The antibody according to any one of the preceding claims, wherein the antibody is derived from germline heavy chain IGHV1-58, such as Omi-12, Beta-47, Beta-25, antibody 55, antibody 165, antibody 253, and antibody 318, and comprises proline at position 53 in the heavy chain variable region.

### Claim 11

A combination of antibodies comprising two or more antibodies according to any one of the preceding claims.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A combination of antibodies comprising:
(a) the antibody according to any one of claims 1 to 10; and
(b) an antibody comprising at least three CDRs of an antibody in Table 1 or Table 2, for example, the antibody comprises:
(i) at least four, five, or all six CDRs of an antibody in Table 1 or Table 2;
(ii) a heavy chain variable domain comprising or consist of an amino acid sequence having at least 80% sequence identity to the heavy chain variable domain of an antibody in Table 1 or Table 2;
(iii) a light chain variable domain comprising or consist of an amino acid sequence having at least 80% sequence identity to the light chain variable domain of an antibody in Table 1 or Table 2; and/or
(iv) a heavy chain variable domain and a light chain variable domain comprising or consist of an amino acid sequence having at least 80% identity to the heavy chain variable domain and light chain domain, respectively, of an antibody in Table 1 or Table 2.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The combination of antibodies according to claim 11 or claim 12, comprising two, three or four antibodies according to any one of claims 1 to 10.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

One or more polynucleotides encoding the antibody according to any one of claims 1 to 10, one or more vectors comprising said polynucleotides, or a host cell comprising said vectors.

### Claim 15 (depends on 14)

A method for producing an antibody that is capable of binding to the spike protein of coronavirus SARS-CoV-2, comprising culturing the host cell of claim 14 and isolating the antibody from said culture.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A pharmaceutical composition comprising: (a) the antibody according to any one of claims 1 to 12, or the combination of antibodies according to any one of claims 11 to 13, and (b) at least one pharmaceutically acceptable diluent or carrier.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16)

The antibody according to any one of claims 1 to 10, the combination according to any one of claims 11 to 13, or the pharmaceutical composition according to claim 16, for use in a method for treatment of the human or animal body by therapy.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16)

The antibody according to any one of claims 1 to 10, the combination according to any one of claims 11 to 13, or the pharmaceutical composition according to claim 16, for use in a method of treating or preventing coronavirus infection, or a disease or complication associated with coronavirus infection.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16)

A method of treating or preventing coronavirus infection, or a disease or complication associated with coronavirus infection in a subject, comprising administering a therapeutically effective amount of the antibody according to any one of claims 1 to 10, the combination according to any one of claims 11 to 13, or the pharmaceutical composition according to claim 16, to said subject.

### Claim 20 (depends on 19, 20)

The method according to claim 19 or 20, wherein the method is for treating SARS-CoV-2 infection, or a disease or complication associated therewith, such as COVID-19.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of identifying the presence of coronavirus, or a protein fragment thereof, in a sample, comprising:
(i) contacting the sample with the antibody according to any one of claims 1 to 10, or the combination according to any one of claims 11 to 13, and
(ii) detecting the presence or absence of an antibody-antigen complex,
wherein the presence of the antibody-antigen complex indicates the presence of coronavirus, or a fragment thereof, in the sample.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 21)

A method of treating or preventing coronavirus infection, or a disease or complication associated therewith, in a subject, comprising identifying the presence of coronavirus according to the method of claim 21 in a sample, and treating the subject with the antibody or combination according to any one of claims 1 to 13, an anti-viral drug or an anti-inflammatory agent.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16)

Use of the antibody according to any one of claims 1 to 10, the combination according to any one of claims 11 to 13, or the pharmaceutical composition according to claim 16, for preventing, treating and/or diagnosing coronavirus infection, or a disease or complication associated therewith.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16)

Use of the antibody according to any one of claims 1 to 10, the combination according to any one of claims 11 to 13, or the pharmaceutical composition according to claim 16, for the manufacture of a medicament for treating or preventing coronavirus infection, or a disease or complication associated therewith.

### Claim 25 (depends on 17, 18, 19, 20, 21, 22, 23, 24)

The antibody for use according to claim 17 or 18, the method according to any one of claims 19 to 22 and the use according to claim 23 or 24, wherein the coronavirus infection is caused by a SARS-CoV-2 strain of the lineage alpha, beta, gamma, delta or omicron, optionally wherein the lineage of the omicron strain is omicron BA.1, omicron BA1.1, omicron BA.2 or omicron BA.3.

### Claim 26

An antibody derived from germline heavy chain IGHV1-58, capable of binding to the spike protein of coronavirus SARS-CoV-2, wherein the amino acid at position 58 in the heavy chain variable region according to IMGT numbering is proline or is substituted with proline.

### Claim 27 (depends on 26)

The antibody of claim 26, wherein the antibody derived from germline heavy chain IGHV1-58 is AZD8895, Omi-12, Beta-47, Beta-25, antibody 55, antibody 165, antibody 253, or antibody 318.

### Claim 28

An antibody capable of binding to the spike protein of coronavirus SARS-CoV-2 comprising a heavy chain variable domain comprising an amino acid sequence having ≥60%, ≥70%, ≥80%, ≥90%, ≥95%, ≥96%, ≥97%, ≥98%, ≥99% or 100% sequence identity to SEQ ID NO: 961, with the proviso that the amino acid at position 58 according to IMGT numbering is proline or is substituted with proline.

### Claim 29 (depends on 26, 27, 28)

The antibody of any one of claims 26 to 28, wherein the antibody comprises a heavy chain variable domain comprising an amino acid sequence having ≥80%, ≥90%, ≥95%, ≥96%, ≥97%, ≥98%, ≥99% or 100% sequence identity to SEQ ID NO: 731, 591, 461, 62, 182, 262, 332 or 963, with the proviso that the amino acid at position 58 according to IMGT numbering is proline or is substituted with proline.

### Claim 30 (depends on 26, 27, 28, 29)

The antibody of any one of claims 26 to 29, wherein the antibody comprises a heavy chain variable domain comprising an amino acid sequence having SEQ ID NO: 591 461, 62, 182, 262, or 332, wherein the valine at position 58 according to IMGT numbering is substituted with a proline.

### Claim 31 (depends on 26, 27, 28, 29)

The antibody of any one of claims 26 to 29, wherein the antibody comprises a heavy chain variable domain comprising an amino acid sequence having SEQ ID NO: 961, wherein the isoleucine at position 58 according to IMGT numbering is substituted with a proline.
